SCHEMBL6022435

SCHEMBL6022435

COc1c(Cl)cc(/C=C/C(=O)O)cc1Cl

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.67
ALDH1A1 P00352 6/20 0.67
HPGD P15428 3/20 0.67
HSD17B10 Q99714 2/20 0.67
HTR1A P08908 1/20 0.67
HTR2C P28335 1/20 0.67
PKM P14618 2/20 0.57
PTGS1 P23219 1/20 0.57
PTGS2 P35354 1/20 0.57
PLA2G1B P04054 1/20 0.53
ATG4B Q9Y4P1 1/20 0.53
SMN1; SMN2 Q16637 2/20 0.51
THRB P10828 1/20 0.51
ATM Q13315 1/20 0.51
ALOX15 P16050 1/20 0.51
MAPK1 P28482 1/20 0.51
GAA P10253 3/20 0.50
LMNA P02545 1/20 0.50
CA12 O43570 1/20 0.49
CA1 P00915 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6022444 1.00 KDM4E (0.67) KDM4EALDH1A1HPGDHSD17B10HTR1A
SCHEMBL11682746 0.80 KDM4E (0.47) KDM4EALDH1A1HPGDHSD17B10HTR1A
SCHEMBL21852876 0.80 KDM4E (0.69) KDM4EALDH1A1HPGDHSD17B10HTR1A
Sinapic Acid Methyl Ether SCHEMBL207441 0.80 KDM4E (1.00) KDM4EALDH1A1HPGDHSD17B10HTR1A
Sinapic Acid Methyl Ether SCHEMBL207442 0.80 KDM4E (1.00) KDM4EALDH1A1HPGDHSD17B10HTR1A
SCHEMBL20600978 0.80 KDM4E (0.69) KDM4EALDH1A1HPGDHSD17B10HTR1A
SCHEMBL9247970 0.80 KDM4E (0.63) KDM4EALDH1A1HPGDHSD17B10HTR1A
SCHEMBL9247967 0.80 KDM4E (0.63) KDM4EALDH1A1HPGDHSD17B10HTR1A
SCHEMBL2391714 0.79 MAOB (0.55) KDM4EALDH1A1HPGDPKMPTGS2
SCHEMBL10480400 0.79 KDM4E (0.67) KDM4EALDH1A1HPGDHSD17B10HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7053071-B2 For therapy of leukemia or other forms of cancer or for treating disease conditions caused by apoptosis of cells THE BURNHAM INSTITUTE (US) 2006-05-30 US disclosed
EP-1456165-A1 INDUCTION OF APOPTOSIS IN CANCER CELLS The Burnham Institute (US) 2004-09-15 EP disclosed
US-20030176506-A1 Induction of apoptosis in cancer cells BURNHAM INSTITUTE FOR MEDICAL RESEARCH 2003-09-18 US disclosed
WO-2003048101-A1 INDUCTION OF APOPTOSIS IN CANCER CELLS THE BURNHAM INSTITUTE (US) 2003-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176506-A1 Induction of apoptosis in cancer cells MCL1, BAD, BCL2 KDM4E 2860/4885ALDH1A1 1651/4885HPGD 803/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.